Literature DB >> 16891629

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.

Karen E Bowker1, Alan R Noel, Alasdair P MacGowan.   

Abstract

OBJECTIVES: The antibacterial effect of dalbavancin was studied against Staphylococcus aureus using stepwise declining concentrations designed to model a range of free drug concentrations observed in human serum.
METHODS: Initial concentrations ranged from 0.6 to 21 mg/L and experiments were conducted over 240 h. Three vancomycin-susceptible and one vancomycin-intermediate strain of S. aureus were used. RESULTS AND
CONCLUSIONS: Dalbavancin showed non-concentration-dependent killing against the three vancomycin-susceptible strains in the range 3-21 mg/L and the vancomycin-intermediate strain at 15 and 21 mg/L. AUC/MIC could be related to antibacterial effect. The AUC/MIC for a bacteriostatic effect was 36 at 24 h, 55 at 120 h and 100 at 240 h. A larger AUC/MIC was required to produce a 2 log reduction in counts, being 214 at 24 h, 195 at 120 h and 331 at 240 h.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891629     DOI: 10.1093/jac/dkl311

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

2.  Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.

Authors:  Pier Giorgio Cojutti; Matteo Rinaldi; Eleonora Zamparini; Nicolò Rossi; Sara Tedeschi; Matteo Conti; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

Review 3.  Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 4.  Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 5.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan Noel; Sharon Tomaselli; Heather Elliott; Karen Bowker
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

Review 7.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 8.  Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Authors:  Sheena Ramdeen; Helen W Boucher
Journal:  Expert Opin Pharmacother       Date:  2015-08-04       Impact factor: 3.889

Review 9.  Dalbavancin.

Authors:  Vanessa R Anderson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.

Authors:  Jason W Bennett; James S Lewis; Michael W Ellis
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.